WASHINGTON (AP) — The Food and Drug Administration has approved a new antibiotic from Durata Therapeutics to treat adults with common skin infections often acquired in U.S. hospitals.
Regulators approved the intravenous drug Dalvance to treat bacterial skin infections caused by common bacteria, including antibiotic-resistant strains of those germs.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.